🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCagriSema (amylin + semaglutide) — my results so far Page 7

CagriSema (amylin + semaglutide) — my results so far

Dr.NutriCornell Wed, Apr 1, 2026 at 9:59 AM 31 replies 1,170 viewsPage 7 of 7
wei_SG
Member
234
890
Nov 2024
Singapore, SG
Apr 7, 2026 at 3:51 AM#31
dan_philly said:
Practical: whatever you change, write down the date and the reason.

Genuinely useful, thank you. I had the facts and not the framework. Printing the relevant bit and taking it with me.

32 7WendyG_ATL, SaraMom3, Dr.MetabolicMD and 29 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Apr 7, 2026 at 1:30 PM#32

Adding the clinical framing, because it changes how the question reads. Start from the measurement rather than the conclusion. Almost every disagreement here turns out to be two people measuring different things and comparing the numbers anyway.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Last edited: Apr 7, 2026 at 3:30 PM
31 6KristenIndy, MarkLI_maint, Dr.PeteFamMed and 28 others
Reply Quote Save Share Report
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Apr 7, 2026 at 11:09 PM#33
VendorMark said:
Start from the measurement rather than the conclusion.

This matches mine closely enough to be worth saying so out loud.

Last edited: Apr 8, 2026 at 2:09 AM
30 5Dr.PulmRoch, maya_sedona, stefan_berlin and 27 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
traveltech_sara
Member
156
678
Jan 2025
Remote, USA
Apr 8, 2026 at 8:47 AM#34
VendorMark said:
Start from the measurement rather than the conclusion.

There is a second half to this that has not been said yet. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

29 4NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 26 others
Reply Quote Save Share Report
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Apr 8, 2026 at 6:25 PM#35

One concrete data point for the thread. The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the same conditions. Nobody wants that answer and it is still the answer.

Last edited: Apr 9, 2026 at 12:25 AM
28 3Dr.MetabolicMD, RetaRick_CA, JenPlateau and 25 others
Reply Quote Save Share Report
1567

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register